PT  - JOURNAL ARTICLE
AU  - Richard Conway
AU  - Carl Orr
AU  - Geraldine M McCarthy
TI  - Lesson of the month 1: Septic arthritis with normal acute phase reactants and white cell count in a patient receiving tocilizumab
AID  - 10.7861/clinmedicine.17-3-280
DP  - 2017 Jun 01
TA  - Clinical Medicine
PG  - 280--281
VI  - 17
IP  - 3
4099  - http://www.rcpjournals.org/content/17/3/280.short
4100  - http://www.rcpjournals.org/content/17/3/280.full
SO  - Clin Med2017 Jun 01; 17
AB  - Septic arthritis represents 8–27% of cases of monoarthritis presenting to the emergency department. Tocilizumab is an interleukin-6 blocking monoclonal antibody with the mechanistic potential to interfere with the body's normal inflammatory response to an infectious insult. We present a case of septic arthritis with a normal white cell count, C-reactive protein, erythrocyte sedimentation rate and fibrinogen in a patient treated with tocilizumab.